Novel therapeutic options for Dravet and Lennox-Gastaut syndrome

References

• Brigo F, Striano P, Balagura G, et al. Emerging drugs for the treatment of Dravet syndrome. Expert Opin Emerg Drugs. 2018;23:261–269.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Striano P, Iapadre G, et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure. 2018;63:17–25.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Cross H. Effects of cannabidiol on drop seizures in the Lennox Gastaut syndrome, GWPCARE3 study group. Effect of cannabidiol on drop seizures in the Lennox-Gastautsyndrome. N Engl J Med. 2018;378:1888–1897.
   PubMed Web of Science ®Google Scholar
• Balagura G, Cacciatore M, Grasso EA, et al. Fenfluramine for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. CNS Drugs. 2020 Oct;34(10):1001–1007.
   PubMed Web of Science ®Google Scholar
• Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of Fenfluramine in scn1a Mutant Zebrafish. Front Pharmacol. 2017;8:191.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131–1139.
   PubMed Web of Science ®Google Scholar
• Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24:309–314.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–2254.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistantseizures in patients with DravetSyndromeReceivingStiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–308.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravetsyndrome. N Engl J Med. 2017;376:2011–2020.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA. GWPCARE1 part A study group. Randomized, dose-ranging safety trial of cannabidiol in Dravetsyndrome. Neurology. 2018;90(14):e1204–e1211.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Cross JH. GWPCARE3 study group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897.
   PubMed Web of Science ®Google Scholar
• GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastautsyndrome (GWPCARE4): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2018;391(10125):1085–1096.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Russo E, et al. Cannabidiol as adjunctive treatment of seizures associated withLennox-Gastautsyndrome and Dravetsyndrome. Drugs Today (Barc). 2019;55(3):177–196.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60(2):294–302.
   PubMed Web of Science ®Google Scholar
• Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients withLennox-Gastautsyndrome: interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–428.
   PubMed Web of Science ®Google Scholar
• Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(5):613–621.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S. Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Rev Neurother. 2020;20(10):1065–1079.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Zaccara G, Russo E, et al. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Expert Rev Neurother. 2020;25:1–12.
   Web of Science ®Google Scholar
• Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015 Nov;8(6):328–338.
   PubMed Web of Science ®Google Scholar
• Lai WW, Galer BS, Wong PC, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020 Aug 18. DOI:https://doi.org/10.1111/epi.16638. [ Online ahead of print].
   Google Scholar
• Kaplan JS, Stella N, Catterall WA, et al. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11229–11234.
   PubMed Web of Science ®Google Scholar
• Gray RA, Stott CG, Jones NA, et al. Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent. Cannabis Cannabinoid Res. 2020;5(2):145–149.
   PubMedGoogle Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label expanded access program. Epilepsy Behav. 2019;98(Pt A):201–206.
   PubMedGoogle Scholar
• Devinsky O, Thiele EA, Wright S, et al. Cannabidiolefficacyindependent of clobazam: meta-analysis of four randomized controlled trials. Acta Neurol Scand. 2020 Jun 26. DOI:https://doi.org/10.1111/ane.13305. [ Online ahead of print].
   Google Scholar
• Anderson LL, Absalom NL, Abelev SV, et al. Coadministeredcannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60(11):2224–2234.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Striano P, et al. Cannabidiolefficacy and clobazam status: A systematic review and meta-analysis. Epilepsia. 2020;61(6):1090–1098.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34(3):229–241.
   PubMed Web of Science ®Google Scholar
• Scala M, Bianchi A, Bisulli F, et al. Advances in genetic testing and optimization of clinical management in children and adults with epilepsy. Expert Rev Neurother. 2020;20(3):251–269.
   PubMed Web of Science ®Google Scholar